On the stock market since 2010, it operates in the world of health and science. It has 3,352 employees. Now — the numbers.
This is an established company with proven profits.
No real growth. Red columns mark years that ended in a loss.
The gap is $46.1M. In times of high interest rates, a gap like that can squeeze a company.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades below its recent peak — about 13% off the top. A pullback, not a collapse.
Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.
Over the last 3 years, sales fell about 3% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
The price action doesn’t yet back an upward turn. Council score: 0/10.
The sales tempo runs behind the sector. Council score: 2/10.
On our five-subject report card, SAFLF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: SAFLF is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.